| __timestamp | BioMarin Pharmaceutical Inc. | United Therapeutics Corporation |
|---|---|---|
| Wednesday, January 1, 2014 | 302156000 | 381287000 |
| Thursday, January 1, 2015 | 402271000 | 452612000 |
| Friday, January 1, 2016 | 476593000 | 316800000 |
| Sunday, January 1, 2017 | 554336000 | 330100000 |
| Monday, January 1, 2018 | 604353000 | 265800000 |
| Tuesday, January 1, 2019 | 680924000 | 336200000 |
| Wednesday, January 1, 2020 | 737669000 | 423900000 |
| Friday, January 1, 2021 | 759375000 | 467000000 |
| Saturday, January 1, 2022 | 854009000 | 487000000 |
| Sunday, January 1, 2023 | 937300000 | 477100000 |
| Monday, January 1, 2024 | 1009025000 |
In pursuit of knowledge
In the competitive landscape of the pharmaceutical industry, understanding the financial strategies of leading companies is crucial. This analysis delves into the Selling, General, and Administrative (SG&A) expenses of United Therapeutics Corporation and BioMarin Pharmaceutical Inc. from 2014 to 2023. Over this period, BioMarin's SG&A expenses have shown a consistent upward trend, increasing by approximately 210%, reflecting their aggressive market expansion and investment in administrative capabilities. In contrast, United Therapeutics has maintained a more stable SG&A expenditure, with a modest increase of around 25% over the same period. This suggests a more conservative approach to operational spending, potentially focusing on efficiency and cost management. The data highlights the contrasting financial strategies of these two industry players, offering insights into their operational priorities and market positioning.
United Therapeutics Corporation vs Catalent, Inc.: SG&A Expense Trends
Breaking Down SG&A Expenses: United Therapeutics Corporation vs Merus N.V.
Comparing SG&A Expenses: United Therapeutics Corporation vs Veracyte, Inc. Trends and Insights
Selling, General, and Administrative Costs: United Therapeutics Corporation vs Agios Pharmaceuticals, Inc.
Operational Costs Compared: SG&A Analysis of United Therapeutics Corporation and Dynavax Technologies Corporation
United Therapeutics Corporation or Taro Pharmaceutical Industries Ltd.: Who Manages SG&A Costs Better?
Cost Management Insights: SG&A Expenses for BioMarin Pharmaceutical Inc. and Walgreens Boots Alliance, Inc.
Operational Costs Compared: SG&A Analysis of BioMarin Pharmaceutical Inc. and Alpine Immune Sciences, Inc.
Breaking Down SG&A Expenses: BioMarin Pharmaceutical Inc. vs TG Therapeutics, Inc.
SG&A Efficiency Analysis: Comparing BioMarin Pharmaceutical Inc. and Rhythm Pharmaceuticals, Inc.
BioMarin Pharmaceutical Inc. and ACADIA Pharmaceuticals Inc.: SG&A Spending Patterns Compared
Comparing SG&A Expenses: BioMarin Pharmaceutical Inc. vs Novavax, Inc. Trends and Insights